← Back to Search

CAR T-cell Therapy

Adoptive Cell Therapy for Cancer

Phase 1
Recruiting
Research Sponsored by Adaptimmune
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who have received at least one dose of GSK adoptive cell therapy agent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate the long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy.

Who is the study for?
This trial is for people who have previously received GSK adoptive cell therapy as a treatment for tumors. They should be able to consent, have finished or withdrawn from a related GSK study, or completed treatment through managed access. Participants must follow local contraception guidelines and have taken at least one dose of the therapy.
What is being tested?
The trial is monitoring the long-term safety of GSK's adoptive cell therapy in patients up to 15 years after their last infusion. It aims to track any late-emerging side effects and overall health outcomes following the treatment.
What are the potential side effects?
Since this is a long-term follow-up study, it focuses on observing any delayed side effects that may arise from previous treatments with GSK adoptive cell therapy rather than introducing new interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have received at least one dose of a GSK cell therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)
Secondary study objectives
Number of deaths
Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples
Hepatitis Viruses
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants receiving ADP adoptive cell therapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

AdaptimmuneLead Sponsor
24 Previous Clinical Trials
10,737 Total Patients Enrolled
GlaxoSmithKlineLead Sponsor
4,815 Previous Clinical Trials
8,384,320 Total Patients Enrolled
5 Trials studying Tumors
1,919 Patients Enrolled for Tumors
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,608 Previous Clinical Trials
6,145,214 Total Patients Enrolled
1 Trials studying Tumors
12 Patients Enrolled for Tumors

Media Library

Tumors Research Study Groups: Participants receiving ADP adoptive cell therapy
Tumors Clinical Trial 2023: GSK adoptive cell therapy Highlights & Side Effects. Trial Name: NCT03391778 — Phase 1
GSK adoptive cell therapy (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03391778 — Phase 1
~130 spots leftby Apr 2032
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top